Back to Search
Start Over
Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
- Source :
-
The Journal of rheumatology [J Rheumatol] 2013 Dec; Vol. 40 (12), pp. 1986-93. Date of Electronic Publication: 2013 Oct 01. - Publication Year :
- 2013
-
Abstract
- Objective: Screening for latent tuberculosis infection (LTBI) is mandatory before initiating biologics in patients with chronic inflammatory arthritis (CIA). However, few studies have evaluated the discrepancies between the results of tuberculin skin test (TST) and interferon-γ release assays (IGRA) in these patients. The purpose of our study was to investigate factors associated with TST and IGRA results in a large cohort of patients with CIA before the introduction of biologics.<br />Methods: A total of 563 consecutive patients with CIA (293 rheumatoid arthritis, 270 spondyloarthritis) and eligible for biologics were prospectively enrolled. Demographic, clinical, and biological data were recorded. Risk factors for LTBI were assessed. All patients underwent a TST, a chest radiograph, and an IGRA test (T-SPOT.TB).<br />Results: Agreement between the 2 tests was low (κ = 0.16). The bacillus Calmette-Guerin (BCG) status was significantly associated with discordance between the 2 tests (p = 0.004). The TST positivity rate was 34.8%. Factors associated with a negative TST were female sex (p = 0.02) and immunosuppressive treatment (p = 0.003). The only LTBI risk factor associated with TST positivity was an abnormal chest radiograph (p = 0.02). T-SPOT.TB was positive in 21.7% of patients and indeterminate in 15.6%. Previous active TB and chest radiograph abnormalities were associated with IGRA positivity (p = 0.008 and p = 3.9 × 10(-5), respectively). The BCG vaccination was associated with negative IGRA (p = 3 × 10(-4)). Indeterminate IGRA results were associated with age, C-reactive protein, and immunosuppressive treatment (p = 0.005, 0.007, and 0.004, respectively).<br />Conclusion: Our data support the combined use of T-SPOT.TB and TST in patients with CIA before biologics introduction. However, despite these good diagnostic values, indeterminate results may complicate the use of IGRA.
- Subjects :
- Adult
Antirheumatic Agents adverse effects
Antirheumatic Agents therapeutic use
BCG Vaccine
Cohort Studies
Cross-Sectional Studies
Female
Humans
Immunocompromised Host
Immunosuppressive Agents adverse effects
Immunosuppressive Agents therapeutic use
Interferon-gamma Release Tests statistics & numerical data
Male
Middle Aged
Predictive Value of Tests
Prospective Studies
Risk Factors
Tuberculin Test statistics & numerical data
Arthritis, Rheumatoid drug therapy
Arthritis, Rheumatoid epidemiology
Arthritis, Rheumatoid microbiology
Interferon-gamma Release Tests standards
Latent Tuberculosis diagnosis
Latent Tuberculosis epidemiology
Latent Tuberculosis immunology
Spondylitis, Ankylosing drug therapy
Spondylitis, Ankylosing epidemiology
Spondylitis, Ankylosing microbiology
Tuberculin Test standards
Subjects
Details
- Language :
- English
- ISSN :
- 0315-162X
- Volume :
- 40
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- The Journal of rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 24085550
- Full Text :
- https://doi.org/10.3899/jrheum.130303